Exact Mass: 443.1776

Thiothixene

C23H29N3O2S2 (443.1701)

Thiothixene is only found in individuals that have used or taken this drug. It is a thioxanthine used as an antipsychotic agent. Its effects are similar to the phenothiazine antipsychotics. [PubChem]Thiothixene acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects). D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AF - Thioxanthene derivatives D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent (Z)-Thiothixene is an antagonist of serotonergic receptor extracted from patent US 20150141345 A1.

8-AHA-cAMP

C16H26N7O6P (443.1682)

8-Aminohexylamino cAMP

C16H26N7O6P (443.1682)

Dathf

C21H25N5O6 (443.1805)

Lucitanib

C26H25N3O4 (443.1845)

C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor

Asteromycin

C16H25N7O8 (443.1765)

pGlu-Gln-Trp

C21H25N5O6 (443.1805)

1-{4-[(N-methyl-glycyl)-amino]-2-oxo-2H-pyrimidin-1-yl}-3-(seryl-amino)-beta-D-1,3-dideoxy-allopyranuronic acid amide|Gougerotin

C16H25N7O8 (443.1765)

Tyr Asp Phe

C22H25N3O7 (443.1692)

Phe Asp Tyr

C22H25N3O7 (443.1692)

Asp Phe Tyr

C22H25N3O7 (443.1692)

Asp Tyr Phe

C22H25N3O7 (443.1692)

Tyr Phe Asp

C22H25N3O7 (443.1692)

Phe Tyr Asp

C22H25N3O7 (443.1692)

Thiothixene

C23H29N3O2S2 (443.1701)

D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AF - Thioxanthene derivatives C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent (Z)-Thiothixene is an antagonist of serotonergic receptor extracted from patent US 20150141345 A1.

N2-Methylisoeugenolyl-deoxyguanosine

C21H25N5O6 (443.1805)

Cys Pro Pro Gln

C18H29N5O6S (443.1838)

Cys Pro Gln Pro

C18H29N5O6S (443.1838)

Cys Gln Pro Pro

C18H29N5O6S (443.1838)

His Asn Ser Ser

C16H25N7O8 (443.1765)

His Ser Asn Ser

C16H25N7O8 (443.1765)

His Ser Ser Asn

C16H25N7O8 (443.1765)

Asn His Ser Ser

C16H25N7O8 (443.1765)

Asn Ser His Ser

C16H25N7O8 (443.1765)

Asn Ser Ser His

C16H25N7O8 (443.1765)

Pro Cys Pro Gln

C18H29N5O6S (443.1838)

Pro Cys Gln Pro

C18H29N5O6S (443.1838)

Pro Pro Cys Gln

C18H29N5O6S (443.1838)

Pro Pro Gln Cys

C18H29N5O6S (443.1838)

Pro Gln Cys Pro

C18H29N5O6S (443.1838)

Pro Gln Pro Cys

C18H29N5O6S (443.1838)

Gln Cys Pro Pro

C18H29N5O6S (443.1838)

Gln Pro Cys Pro

C18H29N5O6S (443.1838)

Gln Pro Pro Cys

C18H29N5O6S (443.1838)

Ser His Asn Ser

C16H25N7O8 (443.1765)

Ser His Ser Asn

C16H25N7O8 (443.1765)

Ser Asn His Ser

C16H25N7O8 (443.1765)

Ser Asn Ser His

C16H25N7O8 (443.1765)

Ser Ser His Asn

C16H25N7O8 (443.1765)

Ser Ser Asn His

C16H25N7O8 (443.1765)

Lometrexol

C21H25N5O6 (443.1805)

C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite C471 - Enzyme Inhibitor > C2692 - Glycinamide Ribonucleotide Formyltransferase Inhibitor D004791 - Enzyme Inhibitors > D005493 - Folic Acid Antagonists D009676 - Noxae > D000963 - Antimetabolites D000970 - Antineoplastic Agents

Fmoc-Hyp(Bzl)-OH

C27H25NO5 (443.1733)

Fmoc-Hyp-OBz

C27H25NO5 (443.1733)

5-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine 2,3-diacetate

C19H26FN3O8 (443.1704)

S 14506

C24H27ClFN3O2 (443.1776)

S-14506 hydrochloride is a potent 5-HT1A agonist, as well as 5-HT2A/2C antagonist. S-14506 hydrochloride displays dopamine antagonist properties by blocking dopamine D2 receptors. S-14506 hydrochloride inhibits the in vivo binding of [3H]raclopride in striatum and olfactory bulbs. S-14506 hydrochloride has the potential for the research of anxiolytic agent[1][2][3].

7-Monodemethyl Minocycline

C22H25N3O7 (443.1692)

C26H25N3O4

C26H25N3O4 (443.1845)

Ningnanmycin

C16H25N7O8 (443.1765)

Fmoc-Tyr(All)-OH

C27H25NO5 (443.1733)

N-(4-{2-[(6s)-2-Amino-4-Oxo-1,4,5,6,7,8-Hexahydropyrido[2,3-D]pyrimidin-6-Yl]ethyl}benzoyl)-L-Glutamic Acid

C21H25N5O6 (443.1805)

Lucitanib

C26H25N3O4 (443.1845)

C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor

Gougerotin

C16H25N7O8 (443.1765)

Ddathf

C21H25N5O6 (443.1805)

[3-Carboxy-2-[3-[(2-hydroxy-3,3-dimethyl-4-phosphonooxybutanoyl)amino]propanoyloxy]propyl]-trimethylazanium

C16H32N2O10P+ (443.1794)

8-(6-aminohexylamino) 3,5-cyclic AMP

C16H26N7O6P (443.1682)

8-chloro-3-methyl-11-[1-(4-pyridylacetyl)piperidin-4-ylidene]-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine

C27H26ClN3O (443.1764)

N-[5-methyl-2-(4-methylphenyl)-3-pyrazolyl]-2-[(7-methyl-4-oxo-2,3-dihydro-1H-cyclopenta[c][1]benzopyran-9-yl)oxy]acetamide

C26H25N3O4 (443.1845)

N-(2,5-dimethylphenyl)-2-[[3-(4-ethylphenoxy)-4-oxo-1-benzopyran-7-yl]oxy]acetamide

C27H25NO5 (443.1733)

3-[7-(3,4-dimethoxyphenyl)-8-imino-7H-benzo[7,8]chromeno[2,3-d]pyrimidin-9(8H)-yl]propan-1-ol

C26H25N3O4 (443.1845)

2-AHA-cAMP

C16H26N7O6P (443.1682)

Phe-Tyr-Asp

C22H25N3O7 (443.1692)

A tripeptide composed of L-phenylalanine, L-tyrosine and L-aspartic acid joined by peptide linkages.

Asp-Phe-Tyr

C22H25N3O7 (443.1692)

2-[(1R,3R,4aR,9aS)-6-[(4-fluorophenyl)carbamoylamino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N,N-dimethylacetamide

C23H26FN3O5 (443.1856)

2-[(1R,3S,4aR,9aS)-6-[[(4-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide

C23H26FN3O5 (443.1856)

2-[(1S,3S,4aR,9aS)-6-[(4-fluorophenyl)carbamoylamino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N,N-dimethylacetamide

C23H26FN3O5 (443.1856)

N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenylanilino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-pyridinecarboxamide

C26H25N3O4 (443.1845)

N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenylanilino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-pyridinecarboxamide

C26H25N3O4 (443.1845)

2-[(1R,3R,4aS,9aR)-6-[[(4-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide

C23H26FN3O5 (443.1856)

2-[(1S,3R,4aR,9aS)-6-[[(4-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide

C23H26FN3O5 (443.1856)

2-[(1R,3S,4aR,9aS)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide

C23H26FN3O5 (443.1856)

2-[(1R,3R,4aS,9aR)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide

C23H26FN3O5 (443.1856)

2-[(1R,3S,4aS,9aR)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide

C23H26FN3O5 (443.1856)

1-[(1S,2aR,8bR)-1-(hydroxymethyl)-4-[(2-methoxyphenyl)-oxomethyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-2-yl]-2-(3-pyridinyl)ethanone

C26H25N3O4 (443.1845)

(1R,2aS,8bS)-1-(hydroxymethyl)-4-[(2-methoxyphenyl)-oxomethyl]-N-phenyl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-2-carboxamide

C26H25N3O4 (443.1845)

1-[(1S,2aS,8bS)-1-(hydroxymethyl)-4-[(4-methoxyphenyl)-oxomethyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-2-yl]-2-(2-pyridinyl)ethanone

C26H25N3O4 (443.1845)

1-[(1S,2aR,8bR)-1-(hydroxymethyl)-4-[(4-methoxyphenyl)-oxomethyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-2-yl]-2-(2-pyridinyl)ethanone

C26H25N3O4 (443.1845)

3-[4-[(2R,3R)-6-acetyl-2-(hydroxymethyl)-1-(3,3,3-trifluoropropyl)-1,6-diazaspiro[3.3]heptan-3-yl]phenyl]benzonitrile

C24H24F3N3O2 (443.1821)

(6R,7R,8S)-8-(hydroxymethyl)-7-[4-(3-methoxyphenyl)phenyl]-4-[oxo(3-pyridinyl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one

C26H25N3O4 (443.1845)

(6S,7S,8S)-8-(hydroxymethyl)-7-[4-(3-methoxyphenyl)phenyl]-4-[oxo(3-pyridinyl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one

C26H25N3O4 (443.1845)

(6R,7S,8S)-8-(hydroxymethyl)-7-[4-(3-methoxyphenyl)phenyl]-4-[oxo(3-pyridinyl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one

C26H25N3O4 (443.1845)

N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenylanilino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-pyridinecarboxamide

C26H25N3O4 (443.1845)

N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenylanilino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-pyridinecarboxamide

C26H25N3O4 (443.1845)

N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenylanilino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-pyridinecarboxamide

C26H25N3O4 (443.1845)

2-[(1S,3S,4aS,9aR)-6-[[(4-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide

C23H26FN3O5 (443.1856)

2-[(1S,3R,4aS,9aR)-6-[[(4-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide

C23H26FN3O5 (443.1856)

2-[(1R,3S,4aS,9aR)-6-[[(4-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide

C23H26FN3O5 (443.1856)

2-[(1R,3R,4aR,9aS)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide

C23H26FN3O5 (443.1856)

2-[(1S,3S,4aS,9aR)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide

C23H26FN3O5 (443.1856)

2-[(1S,3R,4aS,9aR)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide

C23H26FN3O5 (443.1856)

2-[(1S,3S,4aR,9aS)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide

C23H26FN3O5 (443.1856)

2-[(1S,3R,4aR,9aS)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide

C23H26FN3O5 (443.1856)

1-[(1R,2aS,8bS)-1-(hydroxymethyl)-4-[(2-methoxyphenyl)-oxomethyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-2-yl]-2-(3-pyridinyl)ethanone

C26H25N3O4 (443.1845)

1-[(1R,2aR,8bR)-1-(hydroxymethyl)-4-[(2-methoxyphenyl)-oxomethyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-2-yl]-2-(3-pyridinyl)ethanone

C26H25N3O4 (443.1845)

(1S,2aS,8bS)-1-(hydroxymethyl)-4-[(2-methoxyphenyl)-oxomethyl]-N-phenyl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-2-carboxamide

C26H25N3O4 (443.1845)

(1R,2aR,8bR)-1-(hydroxymethyl)-4-[(2-methoxyphenyl)-oxomethyl]-N-phenyl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-2-carboxamide

C26H25N3O4 (443.1845)

(1S,2aR,8bR)-1-(hydroxymethyl)-4-[(2-methoxyphenyl)-oxomethyl]-N-phenyl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-2-carboxamide

C26H25N3O4 (443.1845)

1-[(1R,2aR,8bR)-1-(hydroxymethyl)-4-[(4-methoxyphenyl)-oxomethyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-2-yl]-2-(2-pyridinyl)ethanone

C26H25N3O4 (443.1845)

1-[(1R,2aS,8bS)-1-(hydroxymethyl)-4-[(4-methoxyphenyl)-oxomethyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-2-yl]-2-(2-pyridinyl)ethanone

C26H25N3O4 (443.1845)

(1S,5R)-N-(1,3-benzodioxol-5-yl)-7-[4-(3-methoxyphenyl)phenyl]-3,6-diazabicyclo[3.1.1]heptane-6-carboxamide

C26H25N3O4 (443.1845)

3-[4-[(2S,3S)-6-acetyl-2-(hydroxymethyl)-1-(3,3,3-trifluoropropyl)-1,6-diazaspiro[3.3]heptan-3-yl]phenyl]benzonitrile

C24H24F3N3O2 (443.1821)

3-[4-[(2S,3R)-6-acetyl-2-(hydroxymethyl)-1-(3,3,3-trifluoropropyl)-1,6-diazaspiro[3.3]heptan-3-yl]phenyl]benzonitrile

C24H24F3N3O2 (443.1821)

(6S,7R,8R)-8-(hydroxymethyl)-7-[4-(3-methoxyphenyl)phenyl]-4-[oxo(3-pyridinyl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one

C26H25N3O4 (443.1845)

Tyr-Phe-Asp

C22H25N3O7 (443.1692)

Phe-Asp-Tyr

C22H25N3O7 (443.1692)

Asp-Tyr-Phe

C22H25N3O7 (443.1692)

Tyr-Asp-Phe

C22H25N3O7 (443.1692)

5-[[4-[4-(3-Hydroxy-2,4,5-trimethyl-6-oxocyclohexa-1,4-dien-1-yl)-2-methylbutoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione

C24H29NO5S (443.1766)

8-oxo-Guo

C21H25N5O6 (443.1805)

JNJ-61432059

C25H22FN5O2 (443.1757)

JNJ-61432059 is an oral active and selective negative modulator of AMPAR associated with trans-membrane AMPAR regulatory protein (TARP) γ-8, with a pIC50 of 9.7 for GluA1/γ-8. Exhibits time- and dose-dependent AMPAR/γ-8 receptor occupancy in mouse hippocampus, resulting in robust seizure protection in corneal kindling and pentylenetetrazole (PTZ) anticonvulsant models[1].

n-[4-({[2-(2,3-dihydroxyphenyl)-5-methyl-4,5-dihydro-1,3-oxazol-4-yl](hydroxy)methylidene}amino)butyl]-2,3-dihydroxybenzenecarboximidic acid

C22H25N3O7 (443.1692)

3-[(1,3-dihydroxy-2-{[1-hydroxy-2-(methylamino)ethylidene]amino}propylidene)amino]-4,5-dihydroxy-6-(2-hydroxy-4-iminopyrimidin-1-yl)oxane-2-carboximidic acid

C16H25N7O8 (443.1765)

(2s,3s,4s,5r,6r)-3-{[(2r)-1,3-dihydroxy-2-{[1-hydroxy-2-(methylamino)ethylidene]amino}propylidene]amino}-4,5-dihydroxy-6-(2-hydroxy-4-iminopyrimidin-1-yl)oxane-2-carboximidic acid

C16H25N7O8 (443.1765)

7-hydroxy-3-(7-hydroxy-2,2-dimethylchromen-8-yl)-6-methoxy-5-methyl-2-phenyl-3h-isoindol-1-one

C27H25NO5 (443.1733)

(2s)-2-{[(2s)-1-hydroxy-2-({hydroxy[(2s)-5-hydroxy-3,4-dihydro-2h-pyrrol-2-yl]methylidene}amino)-4-(c-hydroxycarbonimidoyl)butylidene]amino}-3-(1h-indol-3-yl)propanoic acid

C21H25N5O6 (443.1805)

(9s,12s,15s)-9-amino-4,10,13-trihydroxy-12-[(1s)-1-hydroxyethyl]-2-oxa-11,14-diazatricyclo[15.2.2.1³,⁷]docosa-1(19),3(22),4,6,10,13,17,20-octaene-15-carboxylic acid

C22H25N3O7 (443.1692)

(2s,3'r,4's,6's,9'r)-3',4',9'-trihydroxy-6-methoxy-6'-(2-methylprop-1-en-1-yl)-1h-1',7'-diazaspiro[indole-2,5'-tricyclo[7.3.0.0³,⁷]dodecane]-2',3,8'-trione

C22H25N3O7 (443.1692)

2-[(1-hydroxy-2-{[hydroxy(5-hydroxy-3,4-dihydro-2h-pyrrol-2-yl)methylidene]amino}-4-(c-hydroxycarbonimidoyl)butylidene)amino]-3-(1h-indol-3-yl)propanoic acid

C21H25N5O6 (443.1805)

(9s,12s,15s)-9-amino-4,10,13-trihydroxy-12-[(1r)-1-hydroxyethyl]-2-oxa-11,14-diazatricyclo[15.2.2.1³,⁷]docosa-1(19),3(22),4,6,10,13,17,20-octaene-15-carboxylic acid

C22H25N3O7 (443.1692)